The FDA’s Overdue Crackdown on Misleading Pharmaceutical Advertisements

This Viewpoint discusses the enforcement action that the FDA is taking to correct decades of regulatory failure regarding direct-to-consumer pharmaceutical advertising.

Corresponding Author: Martin A. Makary, MD, MPH, Food and Drug Administration, Office of the Commissioner, Bldg 1, Ste 200, Silver Spring, MD 20993 (CommissionersOffice@fda.hhs.gov).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.